All You Need to Know About Eyenovia (EYEN) Rating Upgrade to Buy
Earnings Call Summary | Eyenovia(EYEN.US) Q1 2024 Earnings Conference
The following is a summary of the Eyenovia, Inc. (EYEN) Q1 2024 Earnings Call Transcript:Financial Performance:Eyenovia reported a Q1 2024 net loss of about $10.9 million or $0.23 per share. This incl
Why Fluent Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Fluent Inc (NASDAQ:FLNT) fell sharply during Thursday's session after posting weaker-than-expected quarterly results.Fluent posted adjusted loss of 30 cents per share, versus market expectat
SYTA, DATS and CYN Among Mid-day Movers
Analysts Offer Insights on Healthcare Companies: Eyenovia (EYEN), Alpine Immune Sciences (ALPN) and GoodRx Holdings (GDRX)
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersLucy Scientific Discovery (NASDAQ:LSDI) stock moved upwards by 123.5% to $1.14 during Thursday's pre-market session. The market value of their outstanding shares is at $2.0 million. SINTX Techs
HC Wainwright & Co. : The Eynovia (EYEN.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $12.00.
HC Wainwright & Co. : The Eynovia (EYEN.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $12.00.
HC Wainwright & Co. Reiterates Buy on Eyenovia, Maintains $12 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates Eyenovia (NASDAQ:EYEN) with a Buy and maintains $12 price target.
Eyenovia Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/16/2024 1248.31% HC Wainwright & Co. → $12 Reiterates Buy → Buy 03/19/2024 1248.31% HC Wainwright & Co.
Eyenovia Inc (EYEN) (Q1 2024) Earnings Call Transcript Highlights: Navigating Challenges and ...
Eyenovia Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Financial Results.
Eyenovia Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Financial Results.
Eyenovia | 10-Q: Quarterly report
Eyenovia Provides Updates On Its Myopia Phase III Program And Its 2 FDA Approved Commercial Products, Mydcombi And Clobetasol
Remains on track towards accelerating development of its late-stage product candidate in the multi-billion-dollar pediatric progressive myopia market, MicroPinePreparing for a 3Q 2024 launch of the fi
Eyenovia Q1 2024 GAAP EPS $(0.23) Misses $(0.17) Estimate, Sales $4.993K Miss $816.667K Estimate
Eyenovia (NASDAQ:EYEN) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.17) by 35.29 percent. This is a 53.33 percent decrease over losses of $(0.15) p
Eyenovia Remains on Track Toward Accelerating Devt of MicroPine >EYEN
Eyenovia Remains on Track Toward Accelerating Devt of MicroPine >EYEN
Eyenovia Prepares for 3Q Launch of Ophthalmic Steroid to Treat Inflammation and Pain Following Ocular Surgery >EYEN
Eyenovia Prepares for 3Q Launch of Ophthalmic Steroid to Treat Inflammation and Pain Following Ocular Surgery >EYEN
Press Release: Eyenovia Reports First Quarter 2024 Financial Results and Provides Updates on Its Myopia Phase III Program and Its Two FDA Approved Commercial Products, Mydcombi and Clobetasol
Eyenovia Reports First Quarter 2024 Financial Results and Provides Updates on its Myopia Phase III Program and its Two FDA Approved Commercial Products, Mydcombi and Clobetasol.
Eyenovia 1Q Loss/Shr 23c >EYEN
Eyenovia 1Q Loss/Shr 23c >EYEN
12 Health Care Stocks Moving In Wednesday's Intraday Session
GainersSINTX Techs (NASDAQ:SINT) stock moved upwards by 136.2% to $0.13 during Wednesday's regular session. The company's market cap stands at $15.9 million. The company's, Q1 earnings came out 2 days
Eyenovia to Report First Quarter 2024 Results on Wednesday, May 15th
NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), an ophthalmic company with two FDA-approved products and a late-stage asset in pediatric progressive myopia, today announced that the Company
No Data